New opportunities in tuberculosis prevention: implications for people living with HIV.
Lucia González FernándezEsther C CasasSatvinder SinghGavin J ChurchyardGrania BrigdenEduardo GotuzzoWim VandeveldeSuvanand SahuSevim AhmedovAdeeba KamarulzamanAlfredo Ponce-de-LeónBeatriz GrinsztejnSusan SwindellsPublished in: Journal of the International AIDS Society (2020)
A number of new tools and strategies to make TPT a standard of care in HIV programmes have become available. The new TPT regimens are safe and effective and can be used with current ART, with attention being paid to potential drug-drug interactions between rifamycins and some classes of antiretrovirals. More research and development is needed to optimize TPT for small children, pregnant women and drug-resistant TB (DR-TB). Effective programmatic scale-up can be supported through context-adapted demand creation strategies and the inclusion of TPT in client-centred services, such as differentiated service delivery (DSD) models. Robust collaboration between the HIV and TB programmes represents a unique opportunity to ensure that TB, a preventable and curable condition, is no longer the number one cause of death in PLHIV.
Keyphrases
- health insurance
- mycobacterium tuberculosis
- drug resistant
- antiretroviral therapy
- hiv infected
- healthcare
- pregnant women
- hiv positive
- hiv aids
- human immunodeficiency virus
- hiv testing
- multidrug resistant
- adverse drug
- acinetobacter baumannii
- hepatitis c virus
- mental health
- men who have sex with men
- palliative care
- primary care
- pulmonary tuberculosis
- working memory
- young adults
- drug induced
- risk assessment
- pain management
- pseudomonas aeruginosa
- cystic fibrosis
- electronic health record
- chronic pain
- pregnancy outcomes